Industry News
Pharmaceutical Industry News
As the FDA steadily churns out a…
As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer materials, a commercial for Bristol Myers Squibb’s Cobenfy is taking its turn in the hot seat.
Cybin is shedding its old…
Cybin is shedding its old identity, evolving into Helus Pharma as part of changes that will see its shares move to a different stock exchange.
Fierce reporters break down the…
Fierce reporters break down the forces that shaped biopharma and healthcare in 2025 and what lies ahead in 2026.
Alvotech and Teva’s Eylea…
Alvotech and Teva's Eylea biosimilar has been under FDA review for much of this year. Back in February, the companies said they expected a decision by the end of 2025.
Pharma marketers enter 2026 asking…
Pharma marketers enter 2026 asking where DTC fits in the DTP era. That question, which few foresaw 12 months ago, reflects the fast rise of direct-to-patient programs. The programs are changing how patients access medicines—and
President Trump Reclassifies Marijuana With Executive Order
Marijuana was downgraded from a Schedule I drug to a Schedule III drug on Thursday. The reclassification does not legalize cannabis, but it does ease restrictions on the substance and allows for more research.
Amid rapidly evolving media…
Amid rapidly evolving media consumption habits and a federal push to limit direct-to-consumer drug advertising, pharma companies in 2026 and beyond are on track to continue their migration away from linear TV as the primary
Daiichi Sankyo scored a key FDA…
Daiichi Sankyo scored a key FDA approval for Enhertu in first-line HER2-positive breast cancer but paused a phase 3 trial of its Merck-partnered ADC due to unexpected patient deaths. Takeda plans to file its TYK2
As Medtronic begins rolling out a…
As Medtronic begins rolling out a recently FDA-cleared diabetes management system combining its MiniMed 780G insulin pump and Abbott’s Instinct glucose sensor, the medtech giant has launched a new campaign to promote the duo.
With the failure of a phase 2…
With the failure of a phase 2 trial of Brinsupri in chronic rhinosinusitis without nasal polyps (CRSsNP), Insmed has discontinued its program to develop the newly approved, first-in-class DPPI inhibitor in the indication.
A year after an FDA rejection,…
A year after an FDA rejection, Johnson & Johnson has won approval for a more convenient version of its lung cancer drug Rybrevant to better challenge AstraZeneca’s Tagrisso.
After seeing some of its financial…
After seeing some of its financial momentum slow this year, Bicycle Therapeutics got a push from two U.K. nuclear agencies in the form of up to 440 tons of reprocessed uranium the biotech needs to
As Eli Lilly gears up to support…
As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic and Paralympic Winter Games, the company is drawing parallels between what the Olympics
Within the mammoth defense bill,…
Within the mammoth defense bill, the Biosecure Act has the potential to raise new hurdles for certain life sciences companies from China and their partners.
“Following the withdrawal of…
"Following the withdrawal of Ocaliva from the U.S. market, we are making necessary changes to our business operating model and have filed a WARN notice with the State of New Jersey regarding a planned workforce
The CDC made a major change to the…
The CDC made a major change to the childhood immunization schedule this week, ending a long-standing policy that supports giving all newborns a hepatitis B virus vaccine within 24 hours of birth.
After spending the last decade…
After spending the last decade developing the drug known as ION582 and building relationships with the Angelman syndrome community, Ionis is now expanding that outreach work to include awareness-raising efforts for a broader audience.
Mike Johnson Shuts Door on Key Health Care Vote, and a Dangerous New Drug Hits U.S. Cities
Plus, the subway stop that’s also a museum.
Three months after reporting a win…
Three months after reporting a win in a phase 3 trial of its kidney transplant drug imlifidase, Hansa Biopharma has stumbled in a separate late-stage study of the treatment in another indication, anti-glomerular basement membrane
The PD-1/ADC combo showed an…
The PD-1/ADC combo showed an overall survival benefit as a perioperative treatment in patients with cisplatin-eligible muscle-invasive bladder cancer.